<DOC>
	<DOCNO>NCT01779401</DOCNO>
	<brief_summary>To identify high-risk patient might in-stent thrombosis PCI thromboelastography head-to-head compare two intensified antiplatelet therapeutic strategy double-dosage Clopidogrel triple antiplatelet therapy Cilostazol standard antiplatelet therapy .</brief_summary>
	<brief_title>Clopidogrel Response Evaluation AnTi-Platelet InterVEntion High Thrombotic Risk PCI Patients</brief_title>
	<detailed_description>Study population : Age 18 - 75 , male non-pregnant female ; stable unstable angina evidence myocardial ischemia , patient myocardial infarction ; coronary angiography reveals stenosis lesion ; discovery ADP induce platelet inhibition rate &lt; 50 % MAADP &gt; 47mm via thromboelastography ( indicate low responsiveness Clopidogrel high risk stent thrombosis formation ) ; able understand objective trial , take part voluntarily sign write informed consent form .</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Cilostazol</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<criteria>1 . Age 18 75 , male nonpregnant female ; 2 . Stable unstable angina evidence myocardial ischemia , patient myocardial infarction ; 3 . Coronary angiography reveals stenosis lesion ; 4 . Discovery ADP induce platelet inhibition rate &lt; 50 % MAADP &gt; 47mm via thromboelastography ( indicate low responsiveness Clopidogrel high risk stent thrombosis formation ) ; 5 . Is able understand objective trial , take part voluntarily sign write informed consent form . 1 . Those participated drug therapy equipment clinical trial reach main study endpoint time limit ; 2 . Symptoms severe heart failure ( NYHA Class III ) leave ventricular ejection fraction &lt; 40 % ( ultrasound leave ventricle ngiography ) ; 3 . Pregnant lactating woman ; 4. severely impaired renal function surgery : serum creatinine &gt; 2.0mg/dl ; 5 . Impaired liver function surgery : Serum GPT &gt; 120U/L ; 6 . Bleeding tendency , history active peptic ulcer , history cerebral hemorrhage cavum subarachnoidale bleeding , patient antiplatelet agent anticoagulant treatment contraindication hence unable undergo anticoagulant therapy ; 7 . Patients unable withstand dual antiplatelet therapy due allergy Aspirin , Clopidogrel ticlopidine , heparin , contrast agent , paclitaxel metal ; 8 . Leucocyte &lt; 3.5 x 109 ; and/or platelet &lt; 100,000/mm3 &gt; 750,000/mm3 ; 9 . Patient 's life expectancy le 12 month ; 10 . Patients plan undergo coronary artery bypass graft surgery within 1 year ; 11 . Those wait heart transplant ; 12 . Patients deem researcher low compliance unable abide requirement complete study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>PCI</keyword>
	<keyword>platelet function monitoring</keyword>
	<keyword>Thrombelastography</keyword>
	<keyword>clopidogrel</keyword>
	<keyword>cilostazol</keyword>
	<keyword>in-stent thrombosis</keyword>
</DOC>